Vol.102 No.9 contentsPRACTICA OTO-RHINO-LARYNGOLOGICA
Vol. 102 No. 9 September 2009
Carboplatin and Paclitaxel in a Patient with Metastatic Lung
Carcinoma of Parotid Gland
Keisuke Mizuta, Keiko Fujii, Nansei Yamada,
Bunya Kuze, Mitsuhiro Aoki and Yatsuji Ito
(Gifu University Graduate School of Medicine)
Patients with metastatic regions of carcinoma of the salivary gland have been treated with chemotherapy. Cisplatin, adriamycin and cyslophosphamide are the most active agents against adenocarcinoma-like salivary gland tumors; however, response rates to these agents have been low. Chemotherapy with carboplatin and paclitaxel is used for non-small cell lung cancer. It has been reported that the combination of carboplatin and paclitaxel was effective in some patients with recurrent or metastaic salivary gland malignancies. Weekly low-dose carboplatin and paclitaxel has been reported to have good activity with acceptable toxicity. A 47-year-old patient underwent total parotidectomy for carcinoma ex-pleomorphic adenoma of the parotid gland. He developed multiple lung metastases 5 months later. The lung metastases did not response to CAP (cisplatin, adriamycin, cyslophosphamide) and we therefore began administration of carboplatin and low-dose paclitaxel. One cycle of treatment consisted of carboplatin at an area under the curve of 1.5 and paclitaxel at 80 mg/m2 on days 1, 8 and 15 on a 28-day cycle. After 6 cycles of this treatment, lung metastases partially responded while maintaining good QOL.
Key words :carboplatin, paclitaxel, carcinoma of parotid gland, lung metastasis